Real-World Evoque Data Reassure, but It’s Still Early Days With TTVR

Why It Matters

The data give clinicians confidence to expand TTVR use beyond trial sites, potentially improving outcomes for high‑risk tricuspid regurgitation patients, while highlighting gaps that must be addressed for sustained adoption.

Key Takeaways

• 30‑day mortality 3.1% in 1,034 US TTVR patients.
• Severe bleeding at 30 days 7.9%, down from 10.4% in TRISCEND II.
• New pacemaker implantation 15.9% vs 24.7% in pivotal trial.
• 98.4% achieved mild or less tricuspid regurgitation post‑procedure.
• Long‑term valve durability and thrombosis risk remain unanswered.

Pulse Analysis

The Evoque transcatheter tricuspid valve replacement (TTVR) has entered a pivotal phase as real‑world evidence from the Society of Thoracic Surgeons/American College of Cardiology TVT Registry emerges. Unlike the controlled environment of TRISCEND II, the registry captures outcomes across 82 U.S. centers, reflecting a broader patient mix that includes older, higher‑risk individuals with atrial fibrillation, diabetes, and recent heart‑failure hospitalizations. Early results are encouraging: 30‑day mortality sits at 3.1%, severe bleeding drops to 7.9%, and the need for new pacemakers falls to 15.9%, all improvements over the pivotal trial. Moreover, 98.4% of patients achieved mild or less tricuspid regurgitation, and functional class shifted dramatically, with over 80% moving to NYHA I/II.

These findings matter because they suggest that Evoque can be deployed safely outside elite research centers, expanding access for patients who previously faced limited options. The lower bleeding and pacemaker rates address two of the most cited safety concerns, potentially easing payer hesitancy and supporting broader CMS coverage with evidence development. However, the registry’s limitations—site‑reported data, incomplete follow‑up, and lack of a comparator arm—underscore the need for rigorous post‑marketing studies. Long‑term valve durability, thrombosis risk, and optimal anticoagulation strategies remain unanswered, especially given the low‑pressure tricuspid environment that may predispose to late complications.

Looking ahead, the industry will watch for multi‑year outcomes from both the ongoing TRISCEND II cohort and expanded real‑world registries. Demonstrating sustained mortality benefit, reduced heart‑failure readmissions, and durable valve performance could shift TTVR from a niche, high‑risk intervention to a standard of care for severe tricuspid regurgitation. Stakeholders—including device manufacturers, clinicians, and payers—must collaborate on robust data collection to validate early optimism and guide evidence‑based adoption.